TEVA TEVA PHARMACEUTICAL INDS LTD revenue, earnings and financials
For the quarter ended June 30, 2026, TEVA PHARMACEUTICAL INDS LTD reported revenue of $4.14B (down 0.8% from a year earlier), net income of −$576M and diluted EPS of −$0.49; over the last four quarters revenue was $14.1B and net income $707M; for the fiscal year ended December 2025 revenue was $17.3B, up 4.3% on the year before.
TEVA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $17.3B, gross profit $8.94B, operating income $2.16B, net income $1.41B (margin 8.2%), EPS $1.21
- Fiscal year ended Dec 2024: revenue $16.5B, gross profit $8.06B, operating income −$303M, net income −$1.64B (margin -9.9%), EPS −$1.45
- Fiscal year ended Dec 2023: revenue $15.8B, gross profit $7.65B, operating income $433M, net income −$559M (margin -3.5%), EPS −$0.50
- Fiscal year ended Dec 2022: revenue $14.9B, gross profit $6.97B, operating income −$2.20B, net income −$2.45B (margin -16.4%), EPS −$2.20
- Fiscal year ended Dec 2021: revenue $15.9B, gross profit $7.59B, operating income $1.72B, net income $417M (margin 2.6%), EPS $0.38
TEVA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $4.14B (down 0.8% year over year), net income −$576M, EPS −$0.49
- Quarter ended Mar 31, 2026: revenue $3.98B (up 2.3% year over year), net income $369M, EPS $0.31
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.50B (down 64.5% year over year), net income $481M, EPS $0.42
- Quarter ended Sep 30, 2025: revenue $4.48B (up 3.4% year over year), net income $433M, EPS $0.37
- Quarter ended Jun 30, 2025: revenue $4.18B (up 0.3% year over year), net income $282M, EPS $0.24
- Quarter ended Mar 31, 2025: revenue $3.89B (up 1.9% year over year), net income $214M, EPS $0.18
- Quarter ended Dec 31, 2024 (from the annual report): revenue $4.23B (down 5.1% year over year), net income −$217M, EPS −$0.19
- Quarter ended Sep 30, 2024: revenue $4.33B (up 12.5% year over year), net income −$437M, EPS −$0.39
- Quarter ended Jun 30, 2024: revenue $4.16B (up 7.4% year over year), net income −$846M, EPS −$0.75
- Quarter ended Mar 31, 2024: revenue $3.82B (up 4.3% year over year), net income −$139M, EPS −$0.12
- Quarter ended Dec 31, 2023 (from the annual report): revenue $4.46B (up 14.8% year over year), net income $464M, EPS $0.42
- Quarter ended Sep 30, 2023: revenue $3.85B (up 7.1% year over year), net income $69.0M, EPS $0.06
- Quarter ended Jun 30, 2023: revenue $3.88B (up 2.4% year over year), net income −$872M, EPS −$0.78
- Quarter ended Mar 31, 2023: revenue $3.66B (up 0.0% year over year), net income −$220M, EPS −$0.20
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.88B (down 5.3% year over year), net income −$1.30B, EPS −$1.17
- Quarter ended Sep 30, 2022: revenue $3.60B (down 7.5% year over year), net income $61.0M, EPS $0.05
- Quarter ended Jun 30, 2022: revenue $3.79B (down 3.2% year over year), net income −$251M, EPS −$0.23
- Quarter ended Mar 31, 2022: revenue $3.66B (down 8.1% year over year), net income −$955M, EPS −$0.86
- Quarter ended Dec 31, 2021 (from the annual report): revenue $4.10B, net income −$159M, EPS −$0.14
- Quarter ended Sep 30, 2021: revenue $3.89B, net income $292M, EPS $0.26
TEVA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $1.65B, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $1.25B, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $1.37B, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $1.59B, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $798M, share buybacks n/a
TEVA balance sheet
- Jun 30, 2026: cash $3.66B, total assets $39.9B, total liabilities $32.1B, shareholders' equity $7.75B
- Mar 31, 2026: cash $3.74B, total assets $40.0B, total liabilities $31.8B, shareholders' equity $8.23B
- Dec 31, 2025: cash $3.56B, total assets $40.7B, total liabilities $32.8B, shareholders' equity $7.91B
- Sep 30, 2025: cash $2.20B, total assets $39.9B, total liabilities $32.6B, shareholders' equity $7.25B
- Jun 30, 2025: cash $2.16B, total assets $40.1B, total liabilities $33.3B, shareholders' equity $6.83B
- Mar 31, 2025: cash $1.70B, total assets $38.4B, total liabilities $32.1B, shareholders' equity $6.26B
- Dec 31, 2024: cash $3.30B, total assets $39.3B, total liabilities $33.6B, shareholders' equity $5.37B
- Sep 30, 2024: cash $3.32B, total assets $41.8B, total liabilities $35.4B, shareholders' equity $6.07B
What is TEVA's revenue?
TEVA PHARMACEUTICAL INDS LTD reported $14.1B of revenue over its last four quarters, through June 30, 2026.
Is TEVA profitable?
Yes. TEVA PHARMACEUTICAL INDS LTD earned $707M over the last four quarters.
What is TEVA's EPS?
Diluted earnings per share over the last four quarters were $0.61; −$0.49 in the latest quarter.